New targeted therapy improved survival for patients with KRAS-mutated lung cancer
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS-targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.
A new targeted therapy called divarasib has shown promising results in improving survival rates for patients with KRAS-mutated non-small cell lung cancer (NSCLC), according to a Phase III clinical trial. The study, known as Krascendo 1, compared divarasib with two existing KRAS G12C inhibitors, sotorasib and adagrasib, in patients whose cancer had progressed after prior treatment.
Researchers from The University of Texas MD Anderson Cancer Center led the trial, which involved 338 participants from 151 centers across 26 countries.
Divarasib proved to be more effective than the standard KRAS inhibitors, reducing the risk of disease progression by 42% and the risk of death by 44%. Median overall survival increased to 17.7 months with divarasib, compared to 12 months with sotorasib or adagrasib. Patients treated with divarasib also had a higher likelihood of responding to treatment (58.4%) and a longer duration of response (11.9 months) compared to the control group (32.3% response rate and 6.9 months median duration).
Despite being administered for twice as long, divarasib had fewer severe treatment-related side effects (25%) than the current KRAS-targeted therapies (35%).
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
